{"id":"2lalerg","rwe":[{"pmid":"38541700","year":"2024","title":"In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy.","finding":"","journal":"Life (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"36675006","year":"2023","title":"How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"32269504","year":"2020","title":"Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation.","finding":"","journal":"Dose-response : a publication of International Hormesis Society","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Labo'Life","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["Immunotherapy"],"company":"Labo'Life","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=2LALERG","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:02:07.694690+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:02:21.833807+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:02:13.258418+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=2LALERG","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:02:13.784676+00:00"}},"allNames":["2lalerg"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"2LALERG, marketed by Labo'Life, is a small molecule with an unknown mechanism of action, currently holding a position in the pharmaceutical market without specified primary indications or revenue data. The key strength of 2LALERG lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of detailed clinical trial results and clear primary indications, which may limit its market acceptance and competitive positioning.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"As a small molecule, 2lalerg likely interacts with specific receptors or enzymes on cell surfaces, but the precise molecular details of its mechanism are unknown."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=2lalerg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=2lalerg","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:21:32.093390","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:02:21.833874+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"2lalerg","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02690935","phase":"PHASE4","title":"Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen","status":"COMPLETED","sponsor":"Labo'Life","startDate":"2016-03","conditions":["Seasonal Allergy"],"enrollment":102,"completionDate":"2017-04-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Labo'Life","relationship":"Original Developer"}],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Labo'Life","recentPublications":[{"date":"2024 Mar 12","pmid":"38541700","title":"In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy.","journal":"Life (Basel, Switzerland)"},{"date":"2023 Jan 12","pmid":"36675006","title":"How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March.","journal":"International journal of molecular sciences"},{"date":"2020 Jan-Mar","pmid":"32269504","title":"Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation.","journal":"Dose-response : a publication of International Hormesis Society"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"2LALERG","companyName":"Labo'Life","companyId":"labo-life","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:02:21.833874+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}